Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
22 Junho 2024 - 5:45PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage
biopharmaceutical company, today presented data on the effect of
pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in
development for obesity and metabolic dysfunction-associated
steatohepatitis (MASH), on cardioinflammatory lipids at the
American Diabetes Association’s (ADA) 84th Scientific Sessions.
“Dyslipidemia is one of the most significant
co-morbidities of obesity, impacting up to 70% of patients with
obesity,” said Vipin K. Garg, Ph.D., President and Chief Executive
Officer of Altimmune. “These data add to the differentiated profile
of pemvidutide and reinforce its potential to reduce inflammatory
lipids associated with cardiovascular plaque formation and
cardiovascular risk in patients with obesity.”
Dysregulated lipid profiles in obesity can cause
systemic inflammation and elevate cardiovascular disease (CVD)
risk. To better understand the potential impact of pemvidutide on
lipoprotein and glycoprotein biomarkers of CVD inflammation,
samples were analyzed from the 12-week, randomized
placebo-controlled Phase 1 study of pemvidutide in subjects with
overweight or obesity but not type 2 diabetes. In the study, 34
subjects were randomly assigned 1:1:1:1 to pemvidutide (1.2mg,
1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously
for 12 weeks. Lipidomic, lipoparticle and glycoprotein profiling
was conducted using ultra-high performance liquid
chromatography-mass spectrometry and proton nuclear magnetic
resonance on plasma samples at baseline and after 12 weeks of
treatment.
Serum lipids including total cholesterol, low
density lipoprotein cholesterol (LDL-C), and triglycerides were
reduced by 28%, 26% and 38% respectively. The reductions in each
class of these lipids were not correlated with weight loss,
suggesting that lipid effects were due to the direct impact of
pemvidutide on lipid metabolism. A detailed analysis showed
pemvidutide significantly reduced small dense LDL-C, short-chain
diglycerides with higher degree of saturation,
lysophosphatidylinositols, lysophosphatidylcholines and
sphingolipids, all lipids with a strong association with CVD.
Reductions in GlycA and GlycB, biomarkers of systemic inflammation
that are known to correlate with heart failure, were also observed.
In addition to the reductions in weight and serum lipids, treatment
with pemvidutide resulted in reductions to systolic and diastolic
blood pressure across all dose groups, suggesting that pemvidutide
may have pleiotropic effects that may contribute to decreased CVD
risk.
About Pemvidutide
Pemvidutide is a novel, investigational,
peptide-based GLP-1/glucagon dual receptor agonist in development
for the treatment of obesity and MASH. Activation of the GLP-1 and
glucagon receptors is believed to mimic the complementary effects
of diet and exercise on weight loss, with GLP-1 suppressing
appetite and glucagon increasing energy expenditure. Glucagon is
also recognized as having direct effects on hepatic fat metabolism,
which is believed to lead to rapid reductions in levels of liver
fat and serum lipids. In clinical trials to date, once-weekly
pemvidutide has demonstrated compelling weight loss, robust
reductions in triglycerides, LDL cholesterol, liver fat content and
blood pressure. The U.S. FDA has granted Fast Track designation to
pemvidutide for the treatment of MASH. Pemvidutide recently
completed the MOMENTUM Phase 2 obesity trial and is being studied
in the ongoing IMPACT Phase 2b MASH trial.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
peptide-based therapeutics. The Company is developing pemvidutide,
a GLP-1/glucagon dual receptor agonist for the treatment of obesity
and MASH. For more information, please
visit www.altimmune.com.
Forward-Looking StatementAny statements made in
this press release relating to future financial or business
performance, conditions, plans, prospects, trends, or strategies
and other financial and business matters, including without
limitation, the timing of key milestones for our clinical assets,
and the prospects for the utility of, regulatory approval,
commercializing or selling any product or drug candidates, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. In addition, when or if
used in this press release, the words “may,” “could,” “should,”
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,”
“predict” and similar expressions and their variants, as they
relate to Altimmune, Inc. may identify forward-looking statements.
The Company cautions that these forward-looking statements are
subject to numerous assumptions, risks, and uncertainties, which
change over time. Important factors that may cause actual results
to differ materially from the results discussed in the forward
looking statements or historical experience include risks and
uncertainties, including risks relating to: delays in regulatory
review, manufacturing and supply chain interruptions, access to
clinical sites, enrollment, adverse effects on healthcare systems
and disruption of the global economy; the reliability of the
results of studies relating to human safety and possible adverse
effects resulting from the administration of the Company’s product
candidates; the Company’s ability to manufacture clinical trial
materials on the timelines anticipated; and the success of future
product advancements, including the success of future clinical
trials. Further information on the factors and risks that could
affect the Company's business, financial conditions and results of
operations are contained in the Company’s filings with the U.S.
Securities and Exchange Commission, including under the heading
“Risk Factors” in the Company’s most recent annual report on Form
10-K and our other filings with the SEC, which are available at
www.sec.gov.
Follow @Altimmune, Inc.
on LinkedInFollow
@AltimmuneInc on Twitter
Company Contact:Richard EisenstadtChief
Financial OfficerPhone: 240-654-1450ir@altimmune.com
Investor Contacts:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com
Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke,
BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Altimmune (NASDAQ:ALT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024